| No data available for the use of Copaxone in patients with impaired
renal functioning.
However it is worthy of note that animal studies suggest that immune
complexes are deposited in the renal glomeruli (kidneys).
While the significance of this is undetermined, there is the possibility
patients with impaired renal functioning may be adversely affected.
Additionally, post marketing adverse event reporting lists hematuria
(presence of blood in the urine - indicative of renal disease/disorder)
as frequent (reported in at least 1/100 patients exposed to glatiramer
acetate) and in addition, urinary frequency.
It is unknown whether these events are related to exposure to glatiramer
acetate (Copaxone ®).
|
